MAZE
Maze Therapeutics, Inc.
Latest Form 4:Sale$446KbyBernstein Harold (President, R&D & CMO) · filed Aug 14, 2026
Maze Therapeutics, Inc. (MAZE) has 38 SEC Form 4 filings (114 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Aug 14, 2026.
The most active filer is President, R&D & CMO Bernstein Harold with 12 filings. Insiders have net sold $9.8M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Jason Coloma
- Employees:141
- HQ:South San Francisco, CA, US
- IPO:2025-01-31
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$19.6M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Market Cap
$1.6B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| President, R&D & CMO | Sale | 16,142 | $446K | Aug 14 | SEC ↗ | |
| Chief Executive Officer | Sale | 34,501 | $922K | Aug 5 | SEC ↗ | |
| CSBO | Sale | 7,500 | $205K | Jul 31 | SEC ↗ | |
| Chief Executive Officer | Sale | 34,501 | $1.0M | Jul 2 | SEC ↗ | |
| President, R&D & CMO | Sale | 14,609 | $437K | Jul 2 | SEC ↗ | |
| CSBO | Sale | 7,500 | $210K | Jul 1 | SEC ↗ | |
| Chief Executive Officer | Sale | 3,993 | $104K | Jun 24 | SEC ↗ | |
| Chief Executive Officer | Sale | 23,865 | $622K | Jun 24 | SEC ↗ | |
| President, R&D & CMO | Sale | 14,853 | $381K | Jun 3 | SEC ↗ | |
| Chief Executive Officer | Sale | 6,643 | $174K | Jun 3 | SEC ↗ | |
| CSBO | Sale | 7,500 | $198K | Jun 2 | SEC ↗ | |
| Chief Executive Officer | Sale | 6,982 | $182K | May 27 | SEC ↗ | |
| Chief Executive Officer | Sale | 25,582 | $666K | May 27 | SEC ↗ | |
| President, R&D & CMO | Sale | 15,000 | $393K | May 18 | SEC ↗ | |
Coloma Jason VFirst filing | Chief Executive Officer | Sale | 1,938 | $50K | May 18 | SEC ↗ |
| CSBO | Sale | 7,500 | $190K | May 1 | SEC ↗ | |
| President, R&D & CMO | Sale | 15,000 | $442K | Apr 2 | SEC ↗ | |
| SVP, Finance | Sale | 2,500 | $74K | Apr 2 | SEC ↗ | |
| CSBO | Sale | 7,500 | $220K | Apr 1 | SEC ↗ | |
| President, R&D & CMO | Sale | 15,000 | $736K | Mar 20 | SEC ↗ | |
| President, R&D & CMO | Sale | 30,000 | $1.5M | Mar 12 | SEC ↗ | |
| SVP, Finance | Sale | 5,000 | $226K | Mar 3 | SEC ↗ | |
| CSBO | Sale | 7,500 | $341K | Mar 3 | SEC ↗ | |
| President, R&D & CMO | Sale | 15,000 | $690K | Feb 4 | SEC ↗ | |
| SVP, Finance | Sale | 5,000 | $230K | Feb 4 | SEC ↗ | |
| CSBO | Sale | 7,500 | $332K | Feb 2 | SEC ↗ | |
| SVP, Finance | Sale | 5,000 | $228K | Jan 26 | SEC ↗ | |
| President, R&D & CMO | Sale | 25,156 | $1.0M | Jan 9 | SEC ↗ | |
| Director | Sale | 2,493 | $96K | Jan 8 | SEC ↗ | |
| Director | Sale | 26,920 | $1.1M | Jan 8 | SEC ↗ | |
| SVP, Finance | Sale | 5,000 | $196K | Jan 6 | SEC ↗ | |
| President, R&D & CMO | Sale | 4,432 | $179K | Jan 6 | SEC ↗ | |
| President, R&D & CMO | Sale | 412 | $16K | Jan 6 | SEC ↗ | |
Bachrodt AmyFirst filing | SVP, Finance | Sale | 10,000 | $406K | Dec 31 | SEC ↗ |
Bachrodt AmyFirst filing | SVP, Finance | Sale | 5,000 | $200K | Dec 31 | SEC ↗ |
Dandekar AtulFirst filing | CSBO | Sale | 72,400 | $2.9M | Dec 31 | SEC ↗ |
Dandekar AtulFirst filing | CSBO | Sale | 100 | $4K | Dec 31 | SEC ↗ |
Bernstein HaroldFirst filing | President, R&D & CMO | Sale | 45,000 | $1.8M | Dec 31 | SEC ↗ |
SCHELLER RICHARD HFirst filing | Director | Sale | 20,744 | $464K | Sep 16 | SEC ↗ |
Related companies
Maze Therapeutics, Inc. is in the Healthcare sector.